Paraffin section immunocytochemistry and cytosol-based ligand-binding assays for ER and PR detection in breast cancer: the time has come for more objectivity

Goussard, J

doi:10.1016/s0304-3835(98)00168-2

Cited by 9 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, each hospital contributed tumor blocks from cases diagnosed over the entire range of the study period, so storage conditions were likely unrelated to diagnostic time period. As biochemical assays have a higher rate of error [3], the increasing use of IHC over time is likely to have contributed to the better concordance in the second protocol period, and the best concordance in the most recent protocol period. The switch to IHC reflected both improvement in IHC techniques and the availability of better antibodies for ER expression analysis in fixed, paraffin-embedded tissues.…”

Section: Discussionmentioning

confidence: 99%

“…During this period, an evolving series of assays have been used in routine pathology practice to determine tumor ER expression. These ranged from biochemical extraction assays through immunohistochemical (IHC) assays, initially used on fresh, frozen tissue and, more recently, on fixed paraffin-embedded tumor tissue [3]. The advancing techniques have been facilitated by the development of increasingly sensitive and specific commercial antibodies to the ER [3].…”

Section: Introductionmentioning

confidence: 99%

“…The biochemical extraction assay quantitatively scores the ER ligand-binding ability of all cells in a pathology specimen, including not only carcinoma cells, but also pre-invasive and adjacent non-neoplastic cells [3]. This cellular heterogeneity increases the proportion of false positive results, compared with IHC [3–6].…”

Section: Introductionmentioning

confidence: 99%

“…This cellular heterogeneity increases the proportion of false positive results, compared with IHC [3–6]. IHC pinpoints the ER location within a specimen, distinguishing ER expression in tumor cells from that in adjacent tissue.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study

et al. 2011

View full text Add to dashboard Cite

Background Estrogen receptor (ER) expression predicts tamoxifen response, which halves the risk of breast cancer recurrence. We examined clinical factors associated with concordance between ER expression at diagnosis and centralized re-assay, and the association of concordance with breast cancer recurrence. Materials and Methods We used immunohistochemistry to assess ER expression on archived fixed, paraffin-embedded breast carcinoma tissue excised from women aged 35–69 years, diagnosed 1985–2001 in Jutland, Denmark. We calculated the percentage agreement, positive predictive value (PPV) and negative predictive value (NPV) of ER status at diagnosis and re-assay. We used logistic regression to investigate factors associated with concordance, and its association with recurrence (odds ratios (OR) and associated 95% confidence intervals (95%CI)). Results ER was re-assayed in 91% of patients (n=1530). Concordance was better in ER+ than ER− tumors (PPV=94% versus NPV=75%). Factors associated with concordance included menopausal status, tumor size, surgical procedure, diagnostic period, lymph node status and time to recurrence. ER+ women at diagnosis who re-assayed ER+ were less likely to have recurrent disease (OR=0.49, 95% CI=0.28, 0.86) than those who re-assayed ER−. In originally ER− women, concordance was not associated with recurrence (OR=0.97, 95% CI=0.66, 1.42). Conclusions Several clinical factors were associated with ER assay concordance. Some women were ineffectively treated with tamoxifen, or required but did not receive tamoxifen. We observed almost exactly the protective effect of endocrine therapy among tamoxifen-treated ER+ women whose tumors expressed the ER on re-assay, compared with those ER− on re-assay. Diagnostic pathology results for ER+ tumors appear a valid and useful resource for research studies. However, those for ER− tumors have lower validity. Study-specific considerations regarding the aims, diagnostic period, and consequences of including ER− patients with truly ER+ disease ought to be examined when using diagnostic pathology results for ER− tumors in research studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The current method of choice for determining ER and PR status in breast cancer is IHC. IHC detection of ER and PR status replaced the earlier labor-intensive method which utilized a ligand-binding assay [33]. A representative figure of ER and PR IHC applied to invasive breast carcinoma is shown in Fig.…”

Section: Microscope Based Molecular Diagnostics Immunohistochemistry mentioning

confidence: 99%

From morphologic to molecular: established and emerging molecular diagnostics for breast carcinoma

et al. 2012

View full text Add to dashboard Cite

Molecular Techniques in Cancer Diagnosis and Management

Ross¹,

Gray²,

Mosher³

et al. 2004

Cancer Diagnostics

View full text Add to dashboard Cite

Paraffin section immunocytochemistry and cytosol-based ligand-binding assays for ER and PR detection in breast cancer: the time has come for more objectivity

Cited by 9 publications

References 16 publications

Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study

Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study

From morphologic to molecular: established and emerging molecular diagnostics for breast carcinoma

Molecular Techniques in Cancer Diagnosis and Management

Contact Info

Product

Resources

About